Mostrando las entradas con la etiqueta Childrens. Mostrar todas las entradas
Mostrando las entradas con la etiqueta Childrens. Mostrar todas las entradas

domingo, 11 de octubre de 2020

Geek of the Week: Elizabeth Lawlor brings her lab — and hope for a cancer cure — to Seattle Children’s

(Photo courtesy of Elizabeth Lawlor)

A native of Vancouver, B.C., Dr. Elizabeth Lawlor is thrilled to be back in the Pacific Northwest. And she’s equally excited about joining the research community in Seattle, as Lawlor and her lab have moved to Seattle Children’s Research Institute and the Ben Towne Center for Childhood Cancer Research.

Lawlor, who arrived in June from the University of Michigan, is co-center director for basic and translational science and the associate director for cancer biology at Children’s. She’s also Professor of Pediatrics and adjunct professor in the Department of Laboratory Medicine and Pathology at the University of Washington and an affiliate member of the Fred Hutchinson Cancer Research Center.

In recognition of Childhood Cancer Awareness Month, Lawlor is our latest Geek of the Week.

Lawlor’s research is focused on understanding the fundamental biology of Ewing sarcoma, an aggressive cancer that peaks in adolescents and young adults. She believes that better therapies and cures for childhood cancer are at our fingertips thanks to rapid advances in science and technology.

viernes, 21 de agosto de 2020

New biotech startup GentiBio lands $20M, inks licensing deals with Seattle Children’s and BRI

Boston-based biotech startup GentiBio this week announced a $20 million funding round and licensing deals with two Seattle research institutions.

The company aims to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases by developing engineered regulatory T cells, or Tregs. It is licensing technology from Seattle Children’s Research Institute, Benaroya Research Institute at Virginia Mason (BRI), and Israel-based MIGAL Galilee Research Institute (MIGAL).

Researchers from both Seattle Children’s and BRI helped launch GentiBio. The company is led by longtime biotech and life sciences industry exec Adel Nada.

“The technologies licensed from these premier research institutions are mature and well-differentiated, and will be further optimized in sponsored research collaborations with the scientific teams that discovered them to advance novel and potent therapeutics with the potential to treat and cure serious autoimmune and inflammatory diseases,” Nada said in a statement.

Investors in the seed round include OrbiMed, Novartis Venture Fund, and RA Capital Management.

GeekWire’s coverage this week is underwritten by BCRA

As you plan for the future, consider what spaces will cultivate employee engagement, reflect your brand, and advance your goals. Digital work will continue, but it can’t recreate the energy that physical proximity offers. Think of it this way, you can listen to an album or go to a concert. You’re hearing the same music, but each experience is unique. The same is true for a workplace, and we can help you reimagine your office to maximize your investment.

Hear more about how to rethink your future workspace here

View the original article here



from WordPress https://cybersonday689753477.wordpress.com/2020/08/21/new-biotech-startup-gentibio-lands-20m-inks-licensing-deals-with-seattle-childrens-and-bri/